Never Mind IUCLID: Study Identifies Costs As Biggest Obstacle To SMEs’ REACH Registration

An ECHA-commissioned study finds the substantial cost of REACH compliance has SMEs considering portfolio rationalization, reduced production levels and other tactics to circumvent registration. According to ECHA, the study "confirms uncertainties" about SMEs' intentions as the May 31, 2018 phase-in deadline for low-tonnage chemicals draws closer, and the agency is exploring solutions accordingly.

A significant proportion of small- and medium-sized enterprises may not be in a position to comply with the 2018 registration deadline under the EU’s REACH regulation due to financial burden, according to a newly released study commissioned by the European Chemicals Agency.

SMEs that manufacture or import chemicals or mixtures are considering pulling some or even all of their products from the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography

Over The Counter: EU Omnibus And ESG, What You Need To Know, With CEN Group’s Jasper Crone

 
• By 

HBW Insight catches up with sustainability expert Jasper Crone to find out what consumer health companies need to know about the European Commission's Omnibus simplification package.

AESGP Annual Meeting: European OTC Market Outlook ‘Very Positive’ Thanks To Prevention Trend

 
• By 

The European OTC market grew at double the rate of the global market in the last twelve months, according to IQVIA Consumer Health, driven by a long-term trend for prevention. Consultancy Simon Kucher identifies a desire to live a longer, healthier life as the primary concern behind this trend.

AESGP Annual Meeting: Harmonizing EU VMS Max Levels Could Cost Sector Over €200m

 
• By 

Limited capacity and a two-to-three year timescale for reformulation could mean that many VMS supplements disappear from the market, warns EPPA partner Alexandra Bocquillion, speaking at the AESGP Annual Meeting in Warsaw, Poland.